Trial Profile
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Topotecan (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 03 May 2023 Status changed from recruiting to completed.
- 27 Jun 2022 Planned primary completion date changed from 15 Jul 2022 to 1 Jul 2023.
- 08 Apr 2022 Planned primary completion date changed from 1 Jul 2022 to 15 Jul 2022.